October 5-7 | Arizona Biltmore

Arbor Biotechnologies

Devyn Smith, CEO

Oct. 5 | 10:45am | FLW Ballroom F

Cambridge, MA

(Private)

Arbor Biotechnologies™, a next-generation gene editing company based in Cambridge, MA, is advancing a pipeline of novel gene editing therapeutics to address a wide range of genetic conditions – from the ultra-rare to the most common genetic diseases. The company’s unique suite of optimized gene editors goes beyond the limitations of early editing technologies to unlock access to new gene targets and has fueled a robust pipeline of first-in-class assets focused on diseases of high unmet need.

www.arbor.bio 



By using this website you agree to accept our Privacy Policy and Terms & Conditions